Ginza Icyome Clinic: Hybrid Macrophage Activation Therapy
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
Macrophages serve dual roles as cellular scavengers and tumor microenvironment architects. Ginza Icyome Clinic, located in Tokyo's central district, introduces next-generation immune modulation: Hybrid Macrophage Activation Therapy (MAT).
Macrophage Biology in Cancer Context
Tumor-associated macrophages (TAM) undergo phenotypic shift toward M2 polarization, promoting tumor progression. Simple macrophage activation risks accelerating malignant growth.
Hybrid MAT Breakthrough:
- Maintains M1 phenotype stability through proprietary bioactive factors, suppressing M2 conversion
- Dual administration pathway:
- Weekly IV Infusion: Plant-derived bioactive factors; high safety profile; eliminates xenogeneic serum risk
- Daily Oral ARL: Maintains therapeutic bioactive factor concentrations
Therapy Characteristics
Low Patient Burden: No large-scale blood collection; suitable for debilitated patients
Systemic Immunomodulation: Anti-tumor effects plus chronic pain relief and fatigue recovery
Individualized Dosing: Pre-treatment and intra-therapy immune assessment; dynamic treatment adjustment
Data Source
Ginza Icyome Clinic Immunotherapy Program
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.